Can-Fite Reports 2023 Financial Results and Clinical Update RAMAT GAN, Israel, March 28, 2024 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced financial results and clinical updates for the twelve months ended December 31, 2023. Namodenoson Drug Candidate: 2. Can-Fite Broadens its Strong Intellectual Property (IP) for NASH (MASH): Received Patent ...

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced it received a Notice of Allowance from the Canadian Intellectual Property Office for its patent application titled “An A3 Adenosine Receptor Ligand For Use In Treating Ectopic Fat Accumulation”. This invention addresses the use of Namodenoson for the reduction of l ...

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that it has expanded its out licensing transaction with Ewopharma AG. to include the pancreatic cancer indication of Can-Fite. During 2021, Can-Fite entered into an exclusive distribution agreement for Piclidenoson with Switzerland-based Ewopharma AG for the treat ...

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that the Journal of the European Academy of Dermatology and Venereology (EADV) published an article titled “Efficacy and safety of piclidenoson in plaque psoriasis: Results from a randomized phase 3 clinical trial (COMFORT-1)”. EADV is a top ranked peer reviewed j ...

Exhibit 99.1 Can-Fite Reports Third Quarter 2023 Financial Results and Clinical Update Advanced liver cancer patient in prior Phase II study remains cancer-free 6.9 years after starting treatment with Namodenoson PETACH TIKVA, Israel, November 30, 2023 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced financial results for the nine months ended Sep ...

PETACH TIKVA, Israel, June 1, 2023 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncology, inflammatory and liver diseases, today announced financial results for the three months ended March 31, 2023. Pivotal Phase 3 Liver Cancer Study—Can-Fite's ongoing pivotal Phase 3 liver cancer study is designed to assess Namodenoson in the treatment of patients with advanced hepatocellular carcinoma (HCC) and ...

Financial Performance - Revenues for the year ended December 31, 2022 were $0.81 million, a decrease of $0.04 million, or 4.7%, compared to $0.85 million in 2021[8] - Total revenues for the year ended December 2022 were $810 million, a decrease of 31% compared to $853 million in 2021[37] - Can-Fite's net loss for the year ended December 31, 2022 was $10.17 million, compared with a net loss of $12.61 million for the same period in 2021[26] - Net loss for the year was $10.173 million, compared to a net loss of $12.615 million in 2021, indicating a reduction of about 19%[37] - Basic and diluted net loss per share improved to $0.01 from $0.03 in the previous year[37] - The operating loss for the year was $10.096 million, an improvement from the $12.842 million loss reported in 2021[37] Expenses - Research and development expenses for the year ended December 31, 2022 were $7.76 million, a decrease of $2.09 million, or 21.2%, compared to $9.85 million in 2021[24] - Research and development expenses decreased to $7.763 million from $9.850 million in the previous year, reflecting a reduction of approximately 21%[37] - General and administrative expenses were $3.14 million for the year ended December 31, 2022, a decrease of $0.70 million, or 18.2%, compared to $3.84 million in 2021[25] Cash and Assets - As of December 31, 2022, Can-Fite had cash, cash equivalents, and short-term deposits of $7.97 million, down from $18.90 million at the end of 2021[11] - Total liabilities and shareholders' equity amounted to $9.283 billion, a decrease from $20.253 billion[36] Product Development and Regulatory Approvals - The pivotal Phase III psoriasis trial for Piclidenoson met its primary endpoint, showing a statistically significant improvement in patients compared to placebo[19] - Can-Fite is advancing Namodenoson in a Phase IIb study for NASH, with a focus on its efficacy in treating liver diseases[6] - The company has submitted a market registration plan for Piclidenoson to the EMA and plans to submit to the FDA[3] - Can-Fite's veterinary partner, Vetbiolix, is developing Piclidenoson for canine osteoarthritis, a market projected to reach $3 billion by 2028[4] - Namodenoson has been approved for compassionate use in Romania for patients with advanced liver cancer, following a complete response in a prior study[7] Risks and Future Outlook - The company continues to face risks related to cash flow uncertainties and the need for additional capital to fund operations[38] - Forward-looking statements indicate potential challenges in product development and regulatory approvals, which may impact future performance[38] - The company has not provided specific guidance for future revenues or operational milestones in the current report[38]

● any patents that are issued may not provide meaningful protection; ● we may not be able to develop additional proprietary technologies that are patentable; ● other companies may challenge patents licensed or issued to us; ● other companies may independently develop similar or alternative technologies, or duplicate our technologies; Washington, D.C. 20549 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Or Commission File No. 001-36203 (Name, Telephone, E-mail and/or F ...

As filed with the Securities and Exchange Commission on February 10, 2023 Registration No. 333-269485 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Can-Fite BioPharma Ltd. (Exact name of registrant as specified in its charter) | State of Israel | 2834 | Not applicable | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standard Industrial | (I.R.S. Employer | | incorporation or organi ...

Can-Fite BioPharma Ltd. (Exact name of registrant as specified in its charter) | State of Israel | 2834 | Not applicable | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standard Industrial | (I.R.S. Employer | | incorporation or organization) | Classification Code Number) | Identification No.) | As filed with the Securities and Exchange Commission on January 31, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEME ...